Anti-HIV nucleosides : past, present and future
Author(s)
Bibliographic Information
Anti-HIV nucleosides : past, present and future
（Medical intelligence unit）
Springer , R.G. Landes, c1997
- :international
- :US and Canada
Available at / 3 libraries
-
No Libraries matched.
- Remove all filters.
Note
Includes bibliographical references and index
Description and Table of Contents
Description
In 1985, a broad family of dideoxynucleoside reverse transcriptase inhibitors were identified to be active against a divergent range of HIV in vitro. Three such drugs - AZT, ddC and ddI - had become prescription drugs by 1991. More recently, d4t and 3TC have been added to this nucleoside armamentarium. Indeed, despite their side-effects, insufficient antiviral activity and the propensity of HIV-1 to develop drug resistance, anti-HIV nucleosides have brought about substantial clinical benefits to HIV-1 infected individuals since the mid-1980s. Even with the development of new modalities of AIDS therapy, anti-HIV nucleosides will continue to play a major role in the therapy of HIV-1 infection. This volume discusses the development, rationale, present status, and the future of the use of anti-HIV nucleosides. Standing orders placed before December 31st, 1996 will receive a 10 per cent reduction off the list price of all volumes published with the series between the order date and December 31st, 1997. This offer is on a firm order basis only.
by "Nielsen BookData"